Skip to main content
. Author manuscript; available in PMC: 2020 Dec 15.
Published in final edited form as: Bioorg Med Chem Lett. 2019 Oct 31;29(24):126757. doi: 10.1016/j.bmcl.2019.126757

Figure 2. Cellular activity of compound 13 is consistent with GGTase II inhibition.

Figure 2.

RPMI-8226 cells were incubated for 48 hours in the presence or absence of lovastatin (10 μM, Lov) or varying concentrations of compound 13. A) Cells were lysed using RIPA buffer to generate whole cell lysate or with Triton X-114 to generate a detergent (membrane) fraction and immunoblot analysis was performed for H-Ras, Rap1a (antibody detects only unmodified protein), and Rab6. β-Tubulin and calnexin were used as loading controls for the whole cell lysate and detergent fractions, respectively. Densitometric analysis of Rab6 (normalized to calnexin) for the treated cells normalized to untreated (control) cells is shown as relative intensity (Rel. Int.). The gels are representative of three independent studies. B) Intracellular lambda light chain concentrations were determined via ELISA. Data are expressed as percentage of control (mean ± SD, n=3). The * denotes p<0.05 per t-test and compares treated cells to untreated control cells.